New Cancer Pill Nearly Doubles Survival in Trial

A pill that goes after one of the toughest cancers just delivered what one doctor called "truly transformational" results for patients. Revolution Medicines said on Monday that its drug daraxonrasib nearly doubled survival time in a late-stage trial, with patients living a median 13.2 months compared with 6.7...